Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)

IntroductionBrodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family. It has been approved for the treatment of moderate-to-severe plaque psoriasis after being evaluated in three Phase-3...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Giuseppe Argenziano, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Chiara Franchi, Francesca Maria Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo Valerio Marzano, Matteo Megna, Francesca Sampogna, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2023-07-01
Saila:	Frontiers in Medicine
Gaiak:	brodalumab psoriasis psoriasis treatment psoriatic arthritis real-life
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1196966/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!